2.15 USD
▼-0.08-3.59%
盘后 1.96 0.00%
2026-09-16
市值
$45.02M
市盈率
—
EPS
-1.20
股息率
—
52 周区间
1.79 – 5.18
成交量
39.10K
Beta
0.44
目标价
6.02
52W 低 1.7952W 高 5.18
价格走势
公司简介
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The co...